Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) reached a new 52-week low on Monday . The company traded as low as C$0.01 and last traded at C$0.02, with a volume of 10000 shares changing hands. The stock had previously closed at C$0.02. Aequus Pharmaceuticals Price Performance The firm has a fifty day moving average […]
Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low during trading on Monday . The stock traded as low as C$0.01 and last traded at C$0.02, with a volume of 10000 shares traded. The stock had previously closed at C$0.02. Aequus Pharmaceuticals Trading Down 25.0 % The stock’s 50 day simple […]
Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s stock price hit a new 52-week low on Wednesday . The stock traded as low as C$0.03 and last traded at C$0.03, with a volume of 246000 shares traded. The stock had previously closed at C$0.03. Aequus Pharmaceuticals Price Performance The company has a market cap of […]
Aequus Pharmaceuticals says it will maintain commercial relationship with Sandoz into 2022
There is potential to extend the current partnership beyond February 2022 and expand to include additional products beyond Vistitan and Tacrolimus IR Aequus is a growing specialty pharmaceutical company focused on developing and commercializing high-quality, differentiated products
Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) will maintain its current commercial relationship pertaining to the Vistitan glaucoma drug, with Sandoz into 2022.
As a specialty pharmaceutical company, Aequus Pharmaceuticals is focused on developing, advancing and promoting differentiated products. The product line includes several medications for eye health as well as an anti-rejection drug (Tacrolimus IR) for transplant recipients.